Bank of America Corp DE Sells 125,567 Shares of Perspective Therapeutics, Inc. (NYSE:CATX)

Bank of America Corp DE trimmed its position in shares of Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 72.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,777 shares of the company's stock after selling 125,567 shares during the quarter. Bank of America Corp DE owned 0.07% of Perspective Therapeutics worth $156,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CATX. Y Intercept Hong Kong Ltd bought a new position in Perspective Therapeutics in the fourth quarter valued at approximately $33,000. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the fourth quarter worth $34,000. National Bank of Canada FI lifted its position in Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company's stock valued at $35,000 after acquiring an additional 10,998 shares in the last quarter. Vontobel Holding Ltd. bought a new stake in Perspective Therapeutics in the 4th quarter valued at $51,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Perspective Therapeutics in the 4th quarter worth $51,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Stock Down 0.6%

Shares of NYSE:CATX traded down $0.02 during trading on Friday, hitting $3.43. 417,161 shares of the company were exchanged, compared to its average volume of 1,085,149. The firm has a fifty day moving average price of $2.61 and a two-hundred day moving average price of $2.85. Perspective Therapeutics, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $16.55.

Analysts Set New Price Targets

Several analysts have issued reports on CATX shares. Truist Financial dropped their price target on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a report on Thursday, March 6th. Wedbush reissued an "outperform" rating and issued a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, May 13th. Cantor Fitzgerald raised Perspective Therapeutics to a "strong-buy" rating in a research report on Tuesday, March 4th. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a "strong-buy" rating in a research note on Monday, March 10th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $12.63.

Insider Buying and Selling at Perspective Therapeutics

In other Perspective Therapeutics news, Director Robert F. Williamson III purchased 22,192 shares of the company's stock in a transaction that occurred on Friday, March 28th. The shares were acquired at an average price of $2.27 per share, for a total transaction of $50,375.84. Following the purchase, the director now owns 70,837 shares in the company, valued at approximately $160,799.99. The trade was a 45.62% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Johan M. Spoor acquired 22,026 shares of Perspective Therapeutics stock in a transaction on Friday, March 28th. The shares were bought at an average cost of $2.24 per share, with a total value of $49,338.24. Following the completion of the transaction, the chief executive officer now owns 59,383 shares of the company's stock, valued at approximately $133,017.92. This trade represents a 58.96% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 115,696 shares of company stock worth $256,344 over the last quarter. 3.72% of the stock is currently owned by insiders.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.